A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
Annette B. Vogel(BioNTech (United States)), Ricardo Carrion(Texas Biomedical Research Institute), Camila R. Fontes-Garfias(University of Rochester), Sarah C. Dany(BioNTech (Germany)), Yvonne Feuchter(BioNTech (Germany)), Ye Che(Pfizer (United States)), Charles Y. Tan(United States Military Academy), Danka Pavliakova(Pfizer (United States)), Matthew C. Griffor(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), Joshua A. Lees(Pfizer (United States)), Shannan Hall-Ursone(Texas Biomedical Research Institute), Stephanie Hein(BioNTech (Germany)), Alptekin Güler(BioNTech (Germany)), Stephanie Erbar(BioNTech (Germany)), Journey Cole(Texas Biomedical Research Institute), Julia Schlereth(BioNTech (Germany)), Kristin Tompkins(University of Rochester), Stefanie A. Krumm(BioNTech (Germany)), Jakob Loschko(Pfizer (United States)), Bianca Sänger(BioNTech (Germany)), Isis Kanevsky(Pfizer (United States)), Seungil Han(Pfizer (United States)), Petra Adams‐Quack(BioNTech (Germany)), Parag V. Sahasrabudhe(Pfizer (United States)), Mathias Vormehr(BioNTech (Germany)), Michal Gaži(Texas Biomedical Research Institute), Ellene H. Mashalidis(Pfizer (United States)), Kerstin C. Walzer(BioNTech (Germany)), Arianne Plaschke(BioNTech (Germany)), Christoph Kröner(BioNTech (Germany)), Ferdia Bates(BioNTech (Germany)), Ingrid L. Scully(Pfizer (United States)), Thomas Ziegenhals(BioNTech (Germany)), David Eisel(BioNTech (Germany)), Lena M. Kranz(BioNTech (Germany)), Alexander Muik(BioNTech (Germany)), Kathleen M. Brasky(Texas Biomedical Research Institute), Michael W. Pride(Pfizer (United States)), Mohan S. Maddur(Pfizer (United States)), Ann-Kathrin Wallisch(BioNTech (Germany)), Bernadette Jesionek(BioNTech (Germany)), Hanna Junginger(BioNTech (Germany)), Bonny Gaby Lui(BioNTech (Germany)), André P. Heinen(Johannes Gutenberg University Mainz), Jennifer Obregon(Pfizer (United States)), Guy Singh(Pfizer (United States)), Tara Ciolino(Pfizer (United States)), Diana Schneider(BioNTech (Germany)), Stephanie Fesser(BioNTech (Germany))
Cited by 139
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
|New England Journal of Medicine|2015|1.2k